Fwd: Alzheimers

Dear Dr. Pfeifer,

We met briefly on the train yesterday on the way to Davos.

You mentioned that your company had produced a drug to counter-act Alzheimers. Could you give me its name?

Thanks very much and all the best with your important work.

Sincerely,

Walter Kemp (Canadian, based in Vienna)
International Peace Institute

EFTA00684233

Dear Walter,

Really nice to meet you.

The drug, an Anti-Abeta antibody (Anti-Plaues,) is the first drug in a preventive AD study and runs under the name of Crenezumab. This study is supported by NIH. There are other studies on the same molecule together with Genentech, i.e. phase 2 studies of efficacy and biomarkers.

You will find a lot of information on our web or Internet.

Please let me know if you have specific questions and I am happy to provide you the answers.

Best

Andrea

Prof. Andrea Pfeifer
CEO

EFTA00684232

AC Immune SA
EPFL Innovation Park (please note our new address)
Building B
CH-1015 Lausanne

Phone: +41 21 693 91 23
Mobile: [Redacted]
Fax: +41 21 693 91 20
E-mail: [Redacted]

This e-mail message is confidential and for use of the intended recipient(s) only. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. Unauthorized use or treatment of all or part of this message is strictly prohibited. Unintended recipients: please notify the sender and delete the original message, any attachments and any copies from your computer and back-up system immediately. Thank you.

Terje,

I hope this information on Alzheimer's can be helpful.

Walter

Original Message
From: Andrea Pfeifer [mailto:
Sent: Sunday, January 26, 2014 03:38 AM Eastern Standard Time
To: Walter Kemp
Subject: RE: Alzheimers

Dear Walter,

Really nice to meet you.

The drug, an Anti-Abeta antibody (Anti-Plaues,) is the first drug in a preventive AD study and runs under the name of Crenezumab. This study is supported by NIH. There are other studies on the same molecule together with Genentech, i.e. phase 2 studies of efficacy and biomarkers.

You will find a lot of information on our web or Internet.

Please let me know if you have specific questions and I am happy to provide you the answers.

Best

Andrea

Prof. Andrea Pfeifer
CEO

EFTA00684232

AC Immune SA
EPFL Innovation Park (please note our new address)
Building B
CH-1015 Lausanne

Phone: +41 21 693 91 23
Mobile: [Redacted]
Fax: +41 21 693 91 20
E-mail: [Redacted]

This e-mail message is confidential and for use of the intended recipient(s) only. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. Unauthorized use or treatment of all or part of this message is strictly prohibited. Unintended recipients: please notify the sender and delete the original message, any attachments and any copies from your computer and back-up system immediately. Thank you.

-----Original Message-----
From: Walter Kemp
Sent: 24 January 2014 14:18
To: Andrea Pfeifer
Subject: Alzheimers

Dear Dr. Pfeifer,

We met briefly on the train yesterday on the way to Davos.

You mentioned that your company had produced a drug to counter-act Alzheimers. Could you give me its name?

Thanks very much and all the best with your important work.

Sincerely,

Walter Kemp (Canadian, based in Vienna)
International Peace Institute

EFTA00684233

Sent from my iPhone

Begin forwarded message:

From: Walter Kemp <kemp@lpharg>
Date: January 27, 2014 at 7:32:15 PM GMT+1
To: Terje Rod-Larsen
Cc: Camilla Reksten-Monsen
Subject: Fw: Alzheimers

Terje,

I hope this information on Alzheimer's can be helpful.

Walter

Original Message
From: Andrea Pfeifer [mailto:
Sent: Sunday, January 26, 2014 03:38 AM Eastern Standard Time
To: Walter Kemp
Subject: RE: Alzheimers

Dear Walter,

Really nice to meet you.

The drug, an Anti-Abeta antibody (Anti-Plaues,) is the first drug in a preventive AD study and runs under the name of Crenezumab. This study is supported by NIH. There are other studies on the same molecule together with Genentech, i.e. phase 2 studies of efficacy and biomarkers.

You will find a lot of information on our web or Internet.

Please let me know if you have specific questions and I am happy to provide you the answers.

Best

Andrea

Prof. Andrea Pfeifer
CEO

EFTA00684232

AC Immune SA
EPFL Innovation Park (please note our new address)
Building B
CH-1015 Lausanne

Phone: +41 21 693 91 23
Mobile: [Redacted]
Fax: +41 21 693 91 20
E-mail: [Redacted]

This e-mail message is confidential and for use of the intended recipient(s) only. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. Unauthorized use or treatment of all or part of this message is strictly prohibited. Unintended recipients: please notify the sender and delete the original message, any attachments and any copies from your computer and back-up system immediately. Thank you.

-----Original Message-----
From: Walter Kemp
Sent: 24 January 2014 14:18
To: Andrea Pfeifer
Subject: Alzheimers

Dear Dr. Pfeifer,

We met briefly on the train yesterday on the way to Davos.

You mentioned that your company had produced a drug to counter-act Alzheimers. Could you give me its name?

Thanks very much and all the best with your important work.

Sincerely,

Walter Kemp (Canadian, based in Vienna)
International Peace Institute

EFTA00684233